118 related articles for article (PubMed ID: 33074853)
1. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach.
Chou A; Ahadi M; Arena J; Sioson L; Sheen A; Fuchs TL; Pavlakis N; Clarke S; Kneebone A; Hruby G; Sahni S; Mittal A; Samra J; Gill AJ
Am J Surg Pathol; 2021 Mar; 45(3):394-404. PubMed ID: 33074853
[TBL] [Abstract][Full Text] [Related]
2. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
[TBL] [Abstract][Full Text] [Related]
4. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
5. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.
Ahn S; Lee JC; Kim J; Kim YH; Yoon YS; Han HS; Kim H; Hwang JH
Gut Liver; 2022 Jan; 16(1):129-137. PubMed ID: 33875622
[TBL] [Abstract][Full Text] [Related]
6. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
[TBL] [Abstract][Full Text] [Related]
7. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
8. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
10. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
Polish A; Joseph NE; Marsh RW
Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128
[TBL] [Abstract][Full Text] [Related]
11. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
12. A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy.
Fitzgerald TL; Hunter L; Mosquera C; Jindal C; Biswas T; Zervos E; Efird JT
HPB (Oxford); 2019 Feb; 21(2):204-211. PubMed ID: 30087052
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
[TBL] [Abstract][Full Text] [Related]
14. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
16. Morphological aspects of the hepatic response to neoadjuvant therapy.
Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
[TBL] [Abstract][Full Text] [Related]
17. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
Maeda S; Moore AM; Yohanathan L; Hata T; Truty MJ; Smoot RL; Cleary SP; Nagorney DM; Grotz TE; Park EJ; Girgis MD; Reber HA; Motoi F; Masuda T; Unno M; Kendrick ML; Donahue TR
Surgery; 2020 May; 167(5):803-811. PubMed ID: 31992444
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
Mirkin KA; Hollenbeak CS; Wong J
Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
Czosnyka NM; Borgert AJ; Smith TJ
HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
[TBL] [Abstract][Full Text] [Related]
20. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
